Rebecca Araujo

DocwireNews

The REMEDY trial evaluated the efficacy of remote continuous temperature monitoring (CTM) in patients receiving cytotoxic chemotherapy for acute myeloid leukemia (AML). The results were presented as a poster at the <a href="https://www.hoparx.org/hopa-learn/conferences-events/" target="_blank" rel="noopener">Hematology/Oncology Pharmacy Association Annual Conference 2024</a>.Fever is an early and important sign of infection in patients with febrile neutropenia (FN), so early recognition of fever is critical in this population. The REMEDY trial assessed CTM to identify fever in the ambulatory setting among patients with AML who were undergoing treatment with high-dose cytarabine (HiDAC), which is a therapy associated with a high risk of FN.The trial compared a prospective, interventional cohort with data from a retrospective, preintervention cohort that did not use the CTM device. Conducted at a single center, the study enrolled adult patients with AML who received HiDAC as monotherapy. The CTM device utilized was the TempTraq, which consists of a wireless patch with an associated smart device application. Clinicians have access to the data, and alerts are sent to the patient and clinician when the patient&rsquo;s temperature rises above 38 &deg;C (100.4 &deg;F). Patients were instructed to report to the emergency room (ER) in case of fever.The retrospective cohort included 18 patients, and the intervention cohort included 12. Eleven (35.5%) patients in the retrospective cohort were admitted to the ER or hospital for FN, and 4 were transferred to the intensive care unit (ICU). Six patients assessed in the prospective cohort (50%) were admitted for FN, and no patients were admitted to the ICU. The median hospital length of stay was 7.05 days in the retrospective cohort and 4.10 days in the interventional cohort. Microbiologically defined infections were reported in 9 of 10 patients assessed in the retrospective cohort (90%) compared with no patients in the prospective cohort. No deaths occurred in either cohort.&ldquo;Results showed the CTM appeared to detect FN earlier, as evidenced by lower rates of documented infections, transfers to the ICU, and length of FN hospitalizations,&rdquo; the authors wrote in their study.Nine participants in the prospective cohort completed a questionnaire regarding use of the device. Eight patients reported at least 1 difficulty with the device, and 7 had at least 1 episode of a &ldquo;no data transmission&rdquo; alert being sent due to user error. &ldquo;Consideration of access to broadband and literacy with technology is paramount for future success of a CTM device in the ambulatory care setting,&rdquo; the authors noted.In summary, the authors wrote, &ldquo;Data from this single-center study suggest a CTM device may lead to a higher incidence of ER/hospital visits for FN but lower incidence of ICU transfer, confirmed infection source, and length of hospitalization for FN.&rdquo; They called for larger studies to evaluate if CTM use was associated with better FN outcomes and decreased rates of chemotherapy complications.<h4>Reference</h4>Ketchum EB, Daniels S, Jimenez S, Mian M, Bryan L, Clemmons A. Remote outpatient temperature monitoring for early detection of febrile neutropenia after high-dose cytarabine consolidation chemotherapy (the REMEDY trial). Poster. Presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024; April 3-6, 2024; Tampa, Florida.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Remote Temperature Monitoring May Detect Fever Earlier After HiDAC for AML

HOPA Annual Conference 2024

The REMEDY trial evaluated the efficacy of remote continuous temperature monitoring in patients receiving cytotoxic chemotherapy for acute myeloid leukemia.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe